Show simple item record

dc.contributor.authorTan, Ken-Soon
dc.contributor.authorVardesk, Deepak L.
dc.contributor.authorRaman, Padma
dc.contributor.authorFrazier, Jeremy
dc.contributor.authorJarvis, Elizabeth
dc.date.accessioned2015-02-17
dc.date.accessioned2017-03-01T23:45:30Z
dc.date.available2015-06-09T05:10:20Z
dc.date.available2017-03-01T23:45:30Z
dc.date.issued2014
dc.identifier.issn2161-0959
dc.identifier.doi10.4172/2161-0959.1000157
dc.identifier.urihttp://hdl.handle.net/10072/67927
dc.description.abstractAim: Is once daily low dose extended release niacin effective at lowering phosphate? Background: Serum phosphate levels correlate with mortality in dialysis patients. Current phosphate binders often cause side-effects leading to poor compliance. Niacin has previously been shown to lower serum phosphate in patients with kidney disease. However, at doses previously used (≥ 1 g daily), it is poorly tolerated. Slo-niacin® is a extended release formulation taken once daily. Methods: The study was a single-centre double-blind placebo-controlled randomised cross-over trial in haemodialysis patients. All patients received both active treatment (500 mg Slo-niacin® daily) and matching placebo for 8 weeks each with intervening 2 week washout phase. All patients continued usual phosphate binders and Cinacalcet/vitamin D analogues, although no dose adjustments were permitted. Patients were recruited if they were >18yo, not pregnant and serum phosphate 4 weeks prior to commencement was ≥ 1.8 mmol/L. All gave informed consent. Results: 33 patients were recruited. 1 patient died following emergency cardiac surgery during placebo phase & 3 patients withdrew (2 niacin, 1 placebo, p=NS) leaving 29 for analysis. Extended release niacin significantly reduced serum phosphate compared to placebo (p<0.0014, t-test and ANOVA). Mean absolute difference between groups was -0.35 mmol/L (95% CI -0.62 mmol/L to -0.08 mmol/L) in favour of niacin (p ~ 0.01, t-test). Neither treatment altered calcium levels. Extended release niacin was well tolerated apart from early mild flushing which improved with time. Conclusion: Once daily low dose extended-release niacin is effective at lowering serum phosphate.
dc.description.peerreviewedNo
dc.description.publicationstatusYes
dc.format.extent336998 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherOMICS Group International
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1000157-1
dc.relation.ispartofpageto1000157-6
dc.relation.ispartofissue3
dc.relation.ispartofjournalJournal of Nephrology & Therapeutics
dc.relation.ispartofvolume4
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchcode119999
dc.titleThe Slo-Niacin Trial: A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Extended Release Niacin for Phosphate Lowering in Haemodialysis Patients
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dc.type.codec2
gro.facultyGriffith Health Faculty
gro.rights.copyright© 2014 Tan KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
gro.date.issued2015-06-09T05:10:20Z
gro.hasfulltextFull Text
gro.griffith.authorTan, Ken-Soon


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record